Search research articles
Contact Us
Filters
Showing results (11-20 of 201) with videos related to
Page
of 21
Sort By:
Pharmacoeconomics
|
July 6, 2007
Retrospective economic and outcomes analyses using non-US databases: a review
Lizheng Shi, Eric Q Wu, Meredith Hodges, et al.
Journal of Medical Economics
|
November 6, 2013
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia
Annie Guérin, Lei Chen, Katherine Dea, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 12, 2020
Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective
Hongbo Yang, Yanni Hao, Cynthia Z Qi, et al.
Pharmacoeconomics
|
October 9, 2019
Transparency in Health Economic Modeling: Options, Issues and Potential Solutions
Eric Q Wu, Zheng-Yi Zhou, Jipan Xie, et al.
Postgraduate Medicine
|
February 9, 2012
Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs
Morgan Bron, Maryna Marynchenko, Hongbo Yang, et al.
Cancer Treatment Reviews
|
October 12, 2013
Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis
James Signorovitch, Rajeev Ayyagari, William M Reichmann, et al.
Advances in Therapy
|
June 23, 2022
Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
Yifei Liu, Martha Skup, Min Yang, et al.
Journal of Medical Economics
|
May 14, 2020
Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective
Hongbo Yang, Yanni Hao, Xinglei Chai, et al.
Current Medical Research and Opinion
|
March 20, 2014
Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase
Annie Guérin, Lei Chen, Katherine Dea, et al.
Advances in Therapy
|
August 30, 2022
Correction to: Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
Yifei Liu, Martha Skup, Min Yang, et al.
Page
of 21
Search research articles
Search
Showing results (11-20 of 201) with videos related to
Sort By:
Page
of 21
Pharmacoeconomics
|
July 6, 2007
Retrospective economic and outcomes analyses using non-US databases: a review
Lizheng Shi, Eric Q Wu, Meredith Hodges, et al.
Journal of Medical Economics
|
November 6, 2013
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia
Annie Guérin, Lei Chen, Katherine Dea, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 12, 2020
Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective
Hongbo Yang, Yanni Hao, Cynthia Z Qi, et al.
Pharmacoeconomics
|
October 9, 2019
Transparency in Health Economic Modeling: Options, Issues and Potential Solutions
Eric Q Wu, Zheng-Yi Zhou, Jipan Xie, et al.
Postgraduate Medicine
|
February 9, 2012
Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs
Morgan Bron, Maryna Marynchenko, Hongbo Yang, et al.
Cancer Treatment Reviews
|
October 12, 2013
Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis
James Signorovitch, Rajeev Ayyagari, William M Reichmann, et al.
Advances in Therapy
|
June 23, 2022
Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
Yifei Liu, Martha Skup, Min Yang, et al.
Journal of Medical Economics
|
May 14, 2020
Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective
Hongbo Yang, Yanni Hao, Xinglei Chai, et al.
Current Medical Research and Opinion
|
March 20, 2014
Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase
Annie Guérin, Lei Chen, Katherine Dea, et al.
Advances in Therapy
|
August 30, 2022
Correction to: Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
Yifei Liu, Martha Skup, Min Yang, et al.
Page
of 21